The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of ...

EMA human medicine committee recommends approval of Sanofi’s Sarclisa to treat transplant-ineligible newly diagnosed multiple myeloma: Paris Saturday, November 16, 2024, 09:00 H ...

Sanofi gets rated buy today ... as it has been driving revenue from multiple products rather than a single magic drug.

Regeneron and Sanofi's Dupixent sBLA for treating chronic spontaneous urticaria in patients 12+ gets FDA review, with a ...

the US FDA has approved Sanofi and Regeneron's Dupixent (dupilumab) for COPD - as has China's National Medical Products Administration (NMPA), which announced its approval the same day.

Sanofi is aiming to sign an agreement this weekend to sell control of its consumer health business to Clayton Dubilier & Rice, following a last-ditch attempt by a rival bidder to derail the deal ...

PARIS, Oct 20 (Reuters) - Sanofi (SASY.PA), opens new tab on Sunday reached an agreement on terms to sell a controlling stake in its consumer health unit Opella to U.S. private equity firm Clayton ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

Healx will use its AI-based drug discovery tech to analyze proprietary Sanofi compound data and identify potential rare ...

Sanofi confirmed on Monday plans to sell a controlling stake in its over-the-counter unit to a US investment fund, after employment and investment guarantees relieved political controversy. The ...

PARIS, Oct 16 (Reuters) - French unions have called on workers at Sanofi (SASY.PA), opens new tab to strike from Thursday to protest a planned sale of the pharmaceutical group's consumer health ...

But Sanofi said efforts will focus on difficult-to-treat cancers, both hematological malignancies and solid tumors that have critical unmet medical need, including rare cancers such as multiple ...